Literature DB >> 12570700

Recent advances in peroxisome proliferator-activated receptor science.

Barry G Shearer1, William J Hoekstra.   

Abstract

The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, a set of three receptor sub-types encoded by distinct genes, function as lipid sensors to regulate a broad range of genes in many metabolically active tissues. Synthetic PPAR agonists have exhibited therapeutic benefits in treating diabetes and cardiovascular diseases. The discovery of PPAR-specific ligands has led to significant advancement in our understanding of the structure of these receptor proteins and the molecular mechanism of their ligand-dependent activation. Herein, we present both recent progress in the functional analysis of these orphan receptors and the confirmation of the PPARs as molecular targets for the development of new medicines to treat human metabolic disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570700     DOI: 10.2174/0929867033368295

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  23 in total

1.  Suppression of macrophage inflammatory responses by PPARs.

Authors:  Peter Henson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-19       Impact factor: 11.205

2.  Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorγ activation.

Authors:  Hongyan Yuan; Geeta Upadhyay; Yuzhi Yin; Levy Kopelovich; Robert I Glazer
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-28

3.  Endocrine disruptors and childhood social impairment.

Authors:  Amir Miodovnik; Stephanie M Engel; Chenbo Zhu; Xiaoyun Ye; Latha V Soorya; Manori J Silva; Antonia M Calafat; Mary S Wolff
Journal:  Neurotoxicology       Date:  2010-12-21       Impact factor: 4.294

Review 4.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment?

Authors:  Günther Weindl; Monika Schäfer-Korting; Martin Schaller; Hans Christian Korting
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury.

Authors:  Shenyang Li; Kiran K Nagothu; Varsha Desai; Taewon Lee; William Branham; Carrie Moland; Judit K Megyesi; Mark D Crew; Didier Portilla
Journal:  Kidney Int       Date:  2009-08-26       Impact factor: 10.612

7.  Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.

Authors:  Weiwei Shan; Prajakta S Palkar; Iain A Murray; Emily I McDevitt; Mary J Kennett; Boo Hyon Kang; Harriet C Isom; Gary H Perdew; Frank J Gonzalez; Jeffrey M Peters
Journal:  Toxicol Sci       Date:  2008-07-12       Impact factor: 4.849

8.  Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum.

Authors:  Hui Chen; Yong-Wen He; Wen-Qi Liu; Jing-Hui Zhang
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

9.  Prenatal phthalate exposure and performance on the Neonatal Behavioral Assessment Scale in a multiethnic birth cohort.

Authors:  Stephanie M Engel; Chenbo Zhu; Gertrud S Berkowitz; Antonia M Calafat; Manori J Silva; Amir Miodovnik; Mary S Wolff
Journal:  Neurotoxicology       Date:  2009-04-16       Impact factor: 4.294

Review 10.  A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.

Authors:  Kathryn Z Guyton; Weihsueh A Chiu; Thomas F Bateson; Jennifer Jinot; Cheryl Siegel Scott; Rebecca C Brown; Jane C Caldwell
Journal:  Environ Health Perspect       Date:  2009-05-15       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.